分類: 奥博资本
Tal Zaks to Speak at National Academies of Science, Engineering, and Medicine Committe on June 18th, 20204 from 11-12:30pm ET
Carl Gordon Featured on the Cambridge Associates Unseen Upside Podcast
OrbiMed Raises Over $4.3 Billion Across Private Investment Funds
NEW YORK, October 24, 2023 – OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.
Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technologyenabled healthcare services.
OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.
Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com. Follow us on X (formerly Twitter) @OrbiMed.
Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com
OrbiMed Venture Partner Dimitri Krainc Elected President of American Neurological Association
OrbiMed Expands to Europe, Opens London Office
NEW YORK, May 3, 2023 – OrbiMed is excited to announce the opening of its inaugural London office, located at 22a St. James’s Square. This expansion is a logical culmination of OrbiMed’s many decades of commitment to the European life sciences industry.
“With approximately $1.5 billion currently invested in 50 public or private European companies, OrbiMed is an established leader in the European life sciences industry,” stated Managing Partner Carl Gordon. “We look forward to building on this strong foundation to provide even greater local support for our network of European portfolio companies, entrepreneurs, and limited partners.” Matthew Rizzo, General Partner of OrbiMed said, “As part of this expansion, we will accelerate the availability of credit and financing solutions to support healthcare growth and innovation across Europe.”
OrbiMed’s European business activities include serving as the Portfolio Manager for the Worldwide Healthcare Trust PLC and the Biotech Growth Trust PLC, which currently boast more than $3 billion in combined assets under management.
Dimitrios Weedon, Managing Director, has joined OrbiMed as the initial London-based team member, focusing on structured private credit, growth equity, and royalty monetization opportunities. Further team additions are planned to focus on public and private equity investments. Dimitrios can be reached by email: WeedonD@OrbiMed.com.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com
OrbiMed Sees Boost in Royalty and Credit Practice
Dr. Dimitri Krainc Elected to the National Academy of Medicine
The U-M Biointerfaces Institute welcomes Carl Gordon and Natasha Shervani to its Advisory Board
OrbiMed Names Two New General Partners
NEW YORK, December 7, 2021 – OrbiMed is pleased to announce the promotion of two long-standing team members to General Partner.
Matthew Rizzo and Peter Thompson will join OrbiMed’s six existing General Partners at year-end as management company owners and leaders of the firm. Matthew Rizzo joined OrbiMed in 2010 and leads OrbiMed’s royalty monetization and private credit group. Since that time, OrbiMed has established itself as one of the industry-leading providers of structured royalty/credit healthcare financing solutions, investing nearly $3 billion across 78 royalty and credit investments during the past two decades.
Dr. Peter Thompson joined OrbiMed in 2010, initially as a Venture Partner, and more recently as a Private Equity Partner. Peter has demonstrated organizational and investment leadership, including serving as a Founder or CEO of many OrbiMed portfolio companies. Peter has led numerous transformative investments for the firm, including Synthorx, Principia Biopharma, and VelosBio.
“Peter’s promotion to General Partner is a recognition of his substantial contributions to OrbiMed’s private equity team,” stated Managing Partner Carl Gordon. “We look forward to his growing leadership in the years ahead.”
“We congratulate Matt on his leadership role in OrbiMed’s growth from a niche player to one of the largest providers of private credit and royalty monetization solutions for the life sciences industry,” noted Managing Partner Carter Neild.
“As evidenced by these promotions, OrbiMed is committed to building an institutionalized and enduring organizational structure,” stated Managing Partner Sven Borho. “Our partnership will continue to grow in the years ahead.”
About OrbiMed
OrbiMed is a leading healthcare investment firm, with $18 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com
